Business ❯ Finance ❯ Investments ❯ Securities

Public Companies

Capricor Hit with Multiple Investor Lawsuits After FDA Questions Unagreed Trial Analysis

Investor groups are racing to seek lead‑plaintiff status following the FDA’s decision to extend its review of deramiocel to November 22, 2026.

Securities Suit Targets Blaize Holdings as Multiple Law Firms Seek Lead Plaintiffs

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

Capricor Faces Securities Class Action After FDA Questions Deramiocel Analysis

Securities Class Action Targets UWM Over $603 Million Derivatives Loss and Alleged Over‑Hedging

Multiple Firms Vie to Lead Erasca Securities Suits After April Disclosures

Multiple Firms File Securities Lawsuits After GRAIL’s NHS‑Galleri Trial Failed

Multiple Law Firms Seek Lead Roles in AeroVironment Securities Suit

Securities Class Action Targets Futu After Chinese Regulator Disclosures

U.S. Plaintiff Firms File Securities Class Action Against Futu Over Alleged China Regulatory Violations

Multiple Plaintiff Firms Race to Lead POET Technologies Securities Lawsuit

Investors Race to Lead Regencell Securities Suit as June 23 Deadline Nears

Multiple Law Firms Press Securities Claims Over Sportradar Short‑Seller Reports

Sportradar Faces U.S. Securities Class Action Over Alleged Ties to Black‑Market Betting

Securities Class Action Filed Against POET Technologies Over PFIC Tax Disclosures

Investor Firms Seek Lead Role in Regencell Securities Fraud Case

Plaintiff Firms Seek Lead Plaintiffs in Commvault Securities Suits

Plaintiff Firms Seek Lead Plaintiffs in Upstart Securities Suit Over Model 22

Investors File Securities Suit Against Regencell as Firms Seek Lead Plaintiff

Law Firms Seek Lead Plaintiffs in Gossamer Bio Securities Suit Before June 1 Deadline